CRISPR Historical Cash Flow


USD 63.70  3.20  4.78%   

Analysis of CRISPR Therapeutics cash flow over time is an excellent tool to project CRISPR Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Cash Flow Business Acquisitions and Disposals of 7.2 M or Issuance Purchase of Equity Shares of 284.5 M as it is a great indicator of CRISPR Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.Financial Statement Analysis is way more than just reviewing and evaluating CRISPR Therapeutics prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CRISPR Therapeutics is a good buy for the upcoming year.
Continue to Trending Equities.

CRISPR Therapeutics Capital Expenditure

(83.86 Million)


About CRISPR Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in CRISPR balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which CRISPR's non-liquid assets can be easily converted into cash.

CRISPR Therapeutics Cash Flow Chart

CRISPR Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the CRISPR Therapeutics Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
CRISPR Therapeutics Depreciation Amortization and Accretion is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Depreciation Amortization and Accretion of 17.95 Million. As of 28th of June 2022, Issuance Purchase of Equity Shares is likely to grow to about 284.5 M, while Net Cash Flow from Investing is likely to drop (1.1 B).

Issuance Purchase of Equity Shares

A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.

Net Cash Flow from Financing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from financing activities; from continuing and discontinued operations. Principal components of financing cash flow are: issuance (purchase) of equity shares; issuance (repayment) of debt securities; and payment of dividends & other cash distributions.

Net Cash Flow from Investing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from investing activities; from continuing and discontinued operations. Principal components of investing cash flow are: capital (expenditure) disposal of equipment Capital Expenditure; business (acquisitions) disposition Net Cash Flow Business Acquisitions and Disposals and investment (acquisition) disposal Net Cash Flow Investment Acquisitions and Disposals.

Net Cash Flow from Operations

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.
Most accounts from CRISPR Therapeutics cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into CRISPR Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.CRISPR Therapeutics Depreciation Amortization and Accretion is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Depreciation Amortization and Accretion of 17.95 Million. As of 28th of June 2022, Issuance Purchase of Equity Shares is likely to grow to about 284.5 M, while Net Cash Flow from Investing is likely to drop (1.1 B).

CRISPR Therapeutics cash flow statement Correlations

CRISPR Therapeutics Account Relationship Matchups

CRISPR Therapeutics cash flow statement Accounts

201720182019202020212022 (projected)
Capital Expenditure(7.81 M)(2.77 M)(6.68 M)(18.36 M)(81.7 M)(83.86 M)
Depreciation Amortization and Accretion3.02 M3.52 M4.72 M9.18 M17.95 M19.37 M
Net Cash Flow or Change in Cash and Cash Equivalents(75.76 M)216.9 M489 M236.66 M(245.52 M)(251.99 M)
Issuance Purchase of Equity Shares2.61 M315.93 M430.98 M1.02 B250.94 M284.48 M
Net Cash Flow from Financing2.61 M315.93 M430.98 M1.02 B250.94 M298.65 M
Net Cash Flow from Investing(8.31 M)(2.77 M)1.32 M(541.17 M)(1.04 B)(1.06 B)
Net Cash Flow from Operations(70.09 M)(96.24 M)56.68 M(238.37 M)538.97 M581.52 M
Effect of Exchange Rate Changes on Cash41 K(22 K)15 K40 K(11 K)(11.29 K)
Share Based Compensation18.87 M34.98 M44.06 M66.02 M102.39 M110.47 M

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Current Sentiment - CRSP

CRISPR Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on CRISPR Therapeutics AG. What is your opinion about investing in CRISPR Therapeutics AG? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.